Published 1 day ago • loading... • Updated 9 hours ago

LEO Pharma Buys Worldwide Dersimelagon Rights for up to $435 Million

Summary by WTVB

By Jesus Calero Aug 18 (Reuters) - Danish drugmaker LEO Pharma said on Tuesday it had agreed to acquire worldwide rights to drug candidate dersimelagon from Tanabe Pharma for up ‌to $435 million in up-front and near-term milestone payments. As LEO Pha...

8 Articles

Pharmaphorum

Center

LEO Pharma pens $435m deal for Tanabe Pharma’s dersimelagon

LEO Pharma is betting up to $435m on a pill that could give people with an ultra-rare light sensitivity disorder a way to spend more time outdoors.

9 hours ago

Read Full Article

Reuters

Reposted by

WTVB

Center

LEO Pharma buys worldwide dersimelagon rights for up to $435 million

23 hours ago·London, United Kingdom

Read Full Article

Bloomberg

Center

Leo Pharma Buys Rights to Skin Disease Drug in Latest Deal

23 hours ago·New York, United States

Read Full Article

biopharmadive.com

Center

Leo Pharma buys rare skin disease drug in $435M deal

Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.

1 day ago

Read Full Article

L'AGEFI

LEO Pharma Offers Promising Treatment in Protoporphyry

The Danish dermatological laboratory could pay up to 435 million dollars for dersimelagon, which is expected to be marketed by 2027. Due to the investments associated with this launch, LEO Pharma has lowered its range of adjusted ebitda margin for 2026 from 14% to 16%, instead of 15% to 18%.

1 day ago

Read Full Article

borsen.dk

Leo Pharma in Billion-Dollar Acquisition

Leo Pharma buys a new drug for a rare skin disease for a payment of up to DKK 2.8 billion. Despite an upward adjustment in growth prospects, the acquisition will squeeze profitability for 2026

1 day ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year